HRP20191277T1 - Anti-cd26 antitijela i njihove primjene - Google Patents
Anti-cd26 antitijela i njihove primjene Download PDFInfo
- Publication number
- HRP20191277T1 HRP20191277T1 HRP20191277TT HRP20191277T HRP20191277T1 HR P20191277 T1 HRP20191277 T1 HR P20191277T1 HR P20191277T T HRP20191277T T HR P20191277TT HR P20191277 T HRP20191277 T HR P20191277T HR P20191277 T1 HRP20191277 T1 HR P20191277T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- seq
- variable region
- chain variable
- sequence represented
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 208000032467 Aplastic anaemia Diseases 0.000 claims 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 102000045598 human DPP4 Human genes 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000001728 nano-filtration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (15)
1. Izolirano monoklonsko antitijelo koje specifično vezuje humani CD26, navedeno antitijelo koje sadrži varijabilni region teškog lanca i varijabilni region lakog lanca, gdje navedeni varijabilni region teškog lanca sadrži VH CDR1 koji sadrži sekvencu predstavljenu u SEQ ID NO: 133, VH CDR2 koji sadrži sekvencu predstavljenu u SEQ ID NO: 134, i VH CDR3 koji sadrži sekvencu predstavljenu u SEQ ID NO: 1, i gdje navedeni varijabilni region lakog lanca sadrži VL CDR1 koji sadrži sekvencu predstavljenu u SEQ ID NO: 129, VL CDR2 koji sadrži sekvencu predstavljenu u SEQ ID NO: 130, i VL CDR3 koji sadrži sekvencu predstavljenu u SEQ ID NO: 2, gdje navedeni varijabilni region lakog lanca sadrži aminokiselinsku sekvencu odabranu iz grupe koja se sastoji od SEQ ID NOs: 4, i 6 do 21, i gdje navedeni varijabilni region teškog lanca sadrži aminokiselinsku sekvencu odabranu iz grupe koja se sastoji od SEQ ID NOs: 22 do 47.
2. Antitijelo prema patentnom zahtjevu 1, gdje navedeni varijabilni region lakog lanca sadrži aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 4.
3. Antitijelo prema bilo kojem od prethodnih patentnih zahtjeva, gdje navedeni varijabilni region teškog lanca sadrži aminokiselinsku sekvencu sa SEQ ID NO: 26.
4. Antitijelo prema bilo kojem od prethodnih patentnih zahtjeva, gdje navedeno antitijelo sadrži iste sekvence teškog lanca i iste sekvence lakog lanca kao antitijelo proizvedeno od strane hibridomske stanične linije deponirane u CBA-ICLC u Genovi (Italija) kao PD 12002.
5. Antitijelo prema bilo kojem od prethodnih patentnih zahtjeva, gdje navedeno antitijelo sadrži konstantni region lakog lanca, pri čemu navedeni konstantni region lakog lanca sadrži aminokiselinsku sekvencu koja se sastoji od SEQ ID NO: 48.
6. Antitijelo prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je navedeno antitijelo IgG 2B klase, i/ili gdje navedeno antitijelo sadrži aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 49.
7. Antitijelo prema bilo kojem od patentnih zahtjeva 1 do 6, gdje antitijelo je rekombinantno antitijelo, kimerno antitijelo, fragment antitijela, bispecifično antitijelo, monospecifično antitijelo, ili monovalentno antitijelo.
8. Antitijelo prema bilo kojem od patentnih zahtjeva 1 do 7, gdje antitijelo je proizvedeno iz hibridomske stanične linije deponirane u CBA-ICLC u Genovi (Italija) kao PD 12002.
9. Proces proizvodnje antitijela prema bilo kojem od patentnih zahtjeva 1 do 8, koji obuhvaća korake:
i. osiguravanje hibridomske stanične linije deponirane u CBA-ICLC u Genovi (Italija) kao PD 12002;
ii. kultiviranje navedene stanice domaćina u mediju za kultivaciju; i
iii. dobivanje antitijela iz medija;
iv. po izboru pročišćavanje antitijela, na primjer ekskluzijska kromatografijom, afinitetnom kromatografijom, ion-izmjenjivačkom kromatografijom, filtracijom i/ili nanofiltracijom.
10. Farmaceutska kompozicija koja sadrži najmanje jedno antitijelo prema bilo kojem od patentnih zahtjeva 1 do 8, i po izboru najmanje jedan farmaceutski prihvatljiv ekscipijens.
11. Farmaceutska kompozicija iz patentnog zahtjeva 10 za primjenu kao lijek.
12. Farmaceutska kompozicija iz patentnog zahtjeva 11
(a) za primjenu u sprečavanju i/ili liječenju bolesti kalem protiv domaćina (Graft-versus-Host disease - GvHD), poželjno nakon transplantacije hematopoetskih matičnih stanica, i/ili
(b) za primjenu u sprečavanju i/ili liječenju aplastične anemije, poželjno teške aplastične anemije.
13. Antitijelo prema bilo kojem od patentnih zahtjeva 1 do 8 za primjenu kao lijek.
14. Antitijelo prema bilo kojem od patentnih zahtjeva 1 do 8 za primjenu u sprečavanju i/ili liječenju bolesti kalem protiv domaćina (Graft-versus-Host disease - GvHD), poželjno nakon transplantacije hematopoetskih matičnih stanica, i/ili za primjenu u sprečavanju i/ili liječenju aplastične anemije, poželjno teške aplastične anemije.
15. Pribor koji sadrži:
i. najmanje jedno antitijelo prema bilo kojem od patentnih zahtjeva 1 do 8, i dodatno
ii
a) najmanje jedan imunosupresivni lijek, ili
b) najmanje jedan kortikosteroid i najmanje jedan antihistamin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13425029.9A EP2767549A1 (en) | 2013-02-19 | 2013-02-19 | Anti-CD26 antibodies and uses thereof |
| EP14705767.3A EP2864359B1 (en) | 2013-02-19 | 2014-02-19 | Anti-cd26 antibodies and uses thereof |
| PCT/EP2014/053243 WO2014128168A1 (en) | 2013-02-19 | 2014-02-19 | Anti-cd26 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20191277T1 true HRP20191277T1 (hr) | 2019-10-18 |
| HRP20191277T8 HRP20191277T8 (hr) | 2019-11-01 |
Family
ID=48092884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191277T HRP20191277T8 (hr) | 2013-02-19 | 2019-07-17 | Anti-cd26 antitijela i njihove primjene |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9376498B2 (hr) |
| EP (3) | EP2767549A1 (hr) |
| JP (2) | JP6240195B2 (hr) |
| KR (1) | KR101869589B1 (hr) |
| CN (1) | CN104684931B (hr) |
| AU (1) | AU2014220777B2 (hr) |
| CA (1) | CA2874422C (hr) |
| CY (1) | CY1121980T1 (hr) |
| DK (1) | DK2864359T3 (hr) |
| ES (1) | ES2738283T3 (hr) |
| HK (1) | HK1205151A1 (hr) |
| HR (1) | HRP20191277T8 (hr) |
| HU (1) | HUE045150T2 (hr) |
| IL (1) | IL237244B (hr) |
| LT (1) | LT2864359T (hr) |
| ME (1) | ME03753B (hr) |
| MX (1) | MX357293B (hr) |
| NZ (1) | NZ631111A (hr) |
| PL (1) | PL2864359T3 (hr) |
| PT (1) | PT2864359T (hr) |
| RS (1) | RS59093B1 (hr) |
| RU (1) | RU2662933C2 (hr) |
| SA (1) | SA515360248B1 (hr) |
| SI (1) | SI2864359T1 (hr) |
| TR (1) | TR201910572T4 (hr) |
| WO (1) | WO2014128168A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11242399B2 (en) * | 2013-02-19 | 2022-02-08 | Adienne S.A. | Anti-CD26 antibodies |
| EP2767549A1 (en) * | 2013-02-19 | 2014-08-20 | Adienne S.A. | Anti-CD26 antibodies and uses thereof |
| US10630229B2 (en) * | 2016-10-11 | 2020-04-21 | Kevin Stapleton | Panel mounting bracket with grounding mid-clamp and related methods |
| KR101960414B1 (ko) * | 2016-11-11 | 2019-03-27 | 대한민국 | 사람 유래 dpp-4 유전자를 이용한 당뇨 질환 모델용 형질전환돼지 및 이의 용도 |
| TW201930880A (zh) | 2017-12-22 | 2019-08-01 | 瑞士商艾迪安納股份有限公司 | 用於測定抗－ｃｄ２６配體的生物學活性之定量的細胞法 |
| CN109709337B (zh) * | 2018-12-28 | 2021-09-14 | 江苏众红生物工程创药研究院有限公司 | 人cd26的免疫组化检测试剂盒及其临床应用 |
| US20230295328A1 (en) * | 2020-07-28 | 2023-09-21 | Adienne S.A. | Treatment of idiopathic inflammatory myopathies |
| BR112023022312A2 (pt) | 2021-05-13 | 2023-12-26 | Adienne S A | Métodos de tratamento de dermatomiosite |
| CN117580866A (zh) | 2021-05-13 | 2024-02-20 | 阿迪安股份公司 | 治疗移植物抗宿主病的方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| NL9400309A (nl) * | 1993-11-04 | 1995-06-01 | Eurogenetics Nv | Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26. |
| DE69932644T2 (de) | 1998-04-15 | 2007-08-09 | Genentech, Inc., South San Francisco | Menschliches Protein mit in vitro antiproliferativer Aktivität. |
| EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
| WO2002092127A1 (en) * | 2001-05-11 | 2002-11-21 | Board Of Regents, The University Of Texas System | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
| WO2006078161A1 (en) | 2005-01-24 | 2006-07-27 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| EP1853313B1 (en) | 2005-03-03 | 2018-01-24 | Immunomedics Inc. | Humanized l243 antibodies |
| KR20080039929A (ko) * | 2005-07-22 | 2008-05-07 | 와이스 테라퓨틱스 가부시키가이샤 | 항-ｃｄ26 항체 및 이들의 사용 방법 |
| PE20070458A1 (es) * | 2005-09-14 | 2007-07-05 | Takeda Pharmaceutical | Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa |
| US8846393B2 (en) * | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| RU2331881C1 (ru) * | 2007-03-09 | 2008-08-20 | ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Способ определения риска развития атопических заболеваний у новорожденных детей |
| SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| US20120045435A1 (en) * | 2010-08-18 | 2012-02-23 | Theresa Deisher | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| EP2767549A1 (en) * | 2013-02-19 | 2014-08-20 | Adienne S.A. | Anti-CD26 antibodies and uses thereof |
-
2013
- 2013-02-19 EP EP13425029.9A patent/EP2767549A1/en not_active Withdrawn
-
2014
- 2014-02-19 RU RU2014153440A patent/RU2662933C2/ru active
- 2014-02-19 TR TR2019/10572T patent/TR201910572T4/tr unknown
- 2014-02-19 RS RS20190938A patent/RS59093B1/sr unknown
- 2014-02-19 EP EP19170670.4A patent/EP3536711A1/en not_active Withdrawn
- 2014-02-19 MX MX2014014935A patent/MX357293B/es active IP Right Grant
- 2014-02-19 ME MEP-2019-212A patent/ME03753B/me unknown
- 2014-02-19 DK DK14705767.3T patent/DK2864359T3/da active
- 2014-02-19 LT LTEP14705767.3T patent/LT2864359T/lt unknown
- 2014-02-19 SI SI201431259T patent/SI2864359T1/sl unknown
- 2014-02-19 AU AU2014220777A patent/AU2014220777B2/en active Active
- 2014-02-19 EP EP14705767.3A patent/EP2864359B1/en active Active
- 2014-02-19 HU HUE14705767A patent/HUE045150T2/hu unknown
- 2014-02-19 KR KR1020147035708A patent/KR101869589B1/ko active IP Right Grant
- 2014-02-19 PT PT14705767T patent/PT2864359T/pt unknown
- 2014-02-19 US US14/184,241 patent/US9376498B2/en active Active
- 2014-02-19 WO PCT/EP2014/053243 patent/WO2014128168A1/en active Application Filing
- 2014-02-19 CN CN201480002117.1A patent/CN104684931B/zh active Active
- 2014-02-19 NZ NZ631111A patent/NZ631111A/en unknown
- 2014-02-19 PL PL14705767T patent/PL2864359T3/pl unknown
- 2014-02-19 JP JP2015529076A patent/JP6240195B2/ja active Active
- 2014-02-19 CA CA2874422A patent/CA2874422C/en active Active
- 2014-02-19 ES ES14705767T patent/ES2738283T3/es active Active
-
2015
- 2015-02-16 IL IL237244A patent/IL237244B/en active IP Right Grant
- 2015-04-07 SA SA515360248A patent/SA515360248B1/ar unknown
- 2015-06-18 HK HK15105797.7A patent/HK1205151A1/xx unknown
-
2016
- 2016-05-31 US US15/169,386 patent/US10208126B2/en active Active
-
2017
- 2017-07-10 JP JP2017134896A patent/JP2017221205A/ja active Pending
-
2019
- 2019-07-17 HR HRP20191277T patent/HRP20191277T8/hr unknown
- 2019-07-22 CY CY20191100774T patent/CY1121980T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191277T1 (hr) | Anti-cd26 antitijela i njihove primjene | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| HRP20191824T1 (hr) | Agonistička sredstva za vezivanje tnf receptora | |
| RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
| RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| JP2018521638A5 (hr) | ||
| HRP20221141T1 (hr) | Anti-lag3 protutijela | |
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| JP2018532766A5 (hr) | ||
| HRP20131167T1 (hr) | Antitijela za humani receptor programirane smrti pd-1 | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2015533795A5 (hr) | ||
| JP2013121353A5 (hr) | ||
| JP2011514150A5 (hr) | ||
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| RU2015102069A (ru) | Антитела к биотину и способы их применения | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| JP2013198490A5 (hr) | ||
| JP2013520984A5 (hr) |